High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

At baseline and after intervention, dual-energy x-ray absorptiometry was used to assess BMD, and levels of bone cell, bone formation, and resorption were measured.

Why It Was Studied

Androgen deprivation therapy (ADT) inhibits prostate cancer growth.

Who Took Part

The study group was 24 patients.

The age groups tagged for this paper are middle-aged adults and older adults, men only.

Participants were ≥60 years (mean years, 67.7), had a serum 25-hydroxyvitamin D level <32 ng/mL, and initiated ADT within the previous 6 months.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The subject headings attached to it are Prostatic Neoplasms, Vitamin D, Androgen Antagonists, Bone Density and Osteoporosis.

The authors tagged it with the keywords adverse effects, hormonal therapy and vitamins.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Cancer), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.